Optimizing heart failure treatment using registry data
Part of Heart & circulation clinical trials.
This trial uses a national heart failure registry to see if a new way of monitoring treatment can help optimize therapy for people with heart failure and reduced ejection fraction (a weak heart pump). It may lead to better medication adjustments over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your heart failure has lasted more than 6 months
- Your heart's pumping ability (ejection fraction) is 40% or less
- Your current heart failure treatment is not being adjusted right now
- You are able to understand and follow the study process
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a personalized medication plan can improve health in women hospitalized with heart failure. It aims to find the best treatment combinations for better recovery.
This study looks at whether patients with severe heart failure follow their prescribed medications as recommended by treatment guidelines. The researchers want to understand what helps or prevents patients from taking their medicines correctly, which could improve their heart function and symptoms.
This study tests whether a wearable device that monitors your heart and transmits data to your doctor can help optimize your heart failure medications after hospitalization. The goal is to prevent future hospital visits and improve your health by keeping closer tabs on how your body responds to treatment adjustments.
This study aims to improve heart failure treatment for people who have limited access to care in Denver. If you have heart failure with reduced pumping ability and are a patient in the Denver Health system, this trial may help find better ways to manage your condition.
This trial tests whether it is safe and effective to increase heart failure medications (like ACE inhibitors, ARBs, ARNIs, MRAs, or SGLT-2 inhibitors) without frequent kidney monitoring. It is for people with heart failure and reduced ejection fraction who are not yet on full doses of these medicines.
This study is looking for people who may have undiagnosed heart failure. It tests a self-screening method at home to find heart problems earlier.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.